Compare Stocks › ABBV vs COR

AbbVie Inc. (ABBV) vs Cencora, Inc. (COR): Which Is the Better Buy in 2026?

As of 2026-11-01, ABBV is overvalued at $295, with a DCF intrinsic value of $172 and a margin of safety of -71%. COR is overvalued at $331, with an intrinsic value of $198 and a margin of safety of -67%. Of the two, COR has the wider margin of safety.

ABBV
AbbVie Inc.
$294.89
VS
COR
Cencora, Inc.
$330.84

Rewards

ABBV
  • ★AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • ★Gross margin of 73.7% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • ★AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
COR
  • ★Cencora, Inc. has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • ★Cencora, Inc. scores 95/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
  • ★Free cash flow has grown at a 13.3% CAGR over the past 4 years, demonstrating strong earnings power growth.

Risks

ABBV
  • ⚠Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • ⚠Insiders have sold $8.2M worth of stock in the past 3 months — significant insider liquidation.
  • ⚠Free cash flow has declined at a 9.8% CAGR over the past 4 years — a concerning trend.
COR
  • ⚠Gross margin of 4.0% is low, suggesting a competitive or commodity-like market with limited pricing power.
  • ⚠Each dollar of retained earnings has produced only $0.13 of earning power — shareholders may have been better served by dividends.
  • ⚠FCF yield of 5.1% suggests reasonable valuation assuming continued moderate growth.

Key Valuation Metrics

Learn more →
ABBV
COR
Valuation
N/A
Free Cash Flow
$3.21B
N/A
FCF Yield
5.08%
50.67
Trailing P/E
24.56
18.24
Forward P/E
16.74
Quality & Moat
29.08%
ROIC
21.01%
N/A
ROE
96.87%
73.72%
Gross Margin
3.96%
0.60
PEG Ratio
0.69
Balance Sheet Safety
N/A
Net Debt / Equity
3.60
N/A
Interest Coverage
N/A
2.03
Net Debt / EBITDA
2.10
2.35%
Dividend Yield
0.73%
ABBV: 4Ties: 2COR: 2
ABBVCOR

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

COR

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
COR
$8.81
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$3.56B
Δ Market Cap
+$31.33B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
71.5% Overvalued
Price is 71.5% above estimated fair value
Current Price: $294.89
Fair Value: $172.00
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
COR
67.3% Overvalued
Price is 67.3% above estimated fair value
Current Price: $330.84
Fair Value: $197.81
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

Requires positive FCF to compute implied growth rate.

COR

What growth rate is the market pricing in at $331?

+16.5%
Market-Implied Owner Earnings Growth
Standard FCF implies +9.8%

The market implies +16.5% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +9.8%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
COR
95/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
COR
-2.72
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 77.4%Retail & Other 22.5%
No. of Institutional Holders5,303
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
COR
Insiders 4.3%Institutions 99.3%
No. of Institutional Holders1,888
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
COR
0
Buys (3M)
3
Buys (12M)
Total value (12M): $2.31M
TYLER LAUREN M.
Director
$148,626
@ $270.23 · 2026-06-22
DURCAN DERMOT MARK
Director
$1.10M
@ $274.19 · 2026-06-18
DURCAN DERMOT MARK
Director
$1.07M
@ $266.26 · 2026-05-28
CLYBURN FRANKLIN KING JR.
Director
$1,043
@ $260.75 · 2025-03-11
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
1
Sells (3M)
4
Sells (12M)
Total value (12M): $18.92M
DONOGHOE NICHOLAS
Officer
$8.18M
@ $250.00 · 2026-08-14
PURDUE DAVID RYAN
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
COR
4
Sells (3M)
12
Sells (12M)
Total value (12M): $15.06M
KRIKORIAN LAZARUS
Officer
$298,935
@ $303.18 · 2026-10-01
GREENBERG LON R
Director
$411,264
@ $321.30 · 2026-09-16
KRIKORIAN LAZARUS
Officer
$321,080
@ $325.97 · 2026-09-01
CAMPBELL ELIZABETH S
Officer
$3.66M
@ $324.13 · 2026-08-24
MAUCH ROBERT P.
Chief Executive Officer
$1.35M
@ $358.94 · 2026-02-20
MAUCH ROBERT P.
Chief Executive Officer
$479,160
@ $359.46 · 2026-02-18
MAUCH ROBERT P.
Chief Executive Officer
$1.81M
@ $354.73 · 2026-01-20
CAMPBELL ELIZABETH S
Officer
$1.15M
@ $342.10 · 2025-12-19
BATTAGLIA SILVANA
Officer
$578,565
@ $345.00 · 2025-12-19
MAUCH ROBERT P.
Chief Executive Officer
$1.75M
@ $343.45 · 2025-12-18
KRIKORIAN LAZARUS
Officer
$1.38M
@ $343.23 · 2025-12-17
MAUCH ROBERT P.
Chief Executive Officer
$1.87M
@ $366.64 · 2025-11-18
MAUCH ROBERT P.
Chief Executive Officer
$1.67M
@ $326.80 · 2025-10-20
CAMPBELL ELIZABETH S
Officer
$590,846
@ $313.28 · 2025-10-01
MAUCH ROBERT P.
Chief Executive Officer
$1.48M
@ $290.00 · 2025-09-18
COLLIS STEVEN HOWARD
Officer and Director
$9.09M
@ $289.86 · 2025-09-16
COLLIS STEVEN HOWARD
Officer and Director
$4.23M
@ $289.98 · 2025-08-19
MAUCH ROBERT P.
Chief Executive Officer
$1.46M
@ $293.53 · 2025-08-18
COLLIS STEVEN HOWARD
Officer and Director
$4.27M
@ $292.67 · 2025-07-22
MAUCH ROBERT P.
Chief Executive Officer
$1.46M
@ $294.11 · 2025-07-18
COLLIS STEVEN HOWARD
Officer and Director
$4.27M
@ $292.62 · 2025-06-24
BATTAGLIA SILVANA
Officer
$1.21M
@ $297.40 · 2025-06-18
MAUCH ROBERT P.
Chief Executive Officer
$1.47M
@ $295.30 · 2025-06-18
KRIKORIAN LAZARUS
Officer
$866,881
@ $288.96 · 2025-05-29
COLLIS STEVEN HOWARD
Officer and Director
$4.28M
@ $293.84 · 2025-05-20
MAUCH ROBERT P.
Chief Executive Officer
$1.45M
@ $291.43 · 2025-05-19
GREENBERG LON R
Director
$837,150
@ $279.05 · 2025-05-14
COLLIS STEVEN HOWARD
Officer and Director
$4.11M
@ $281.81 · 2025-04-22
MAUCH ROBERT P.
Chief Executive Officer
$1.44M
@ $289.33 · 2025-04-21
COLLIS STEVEN HOWARD
Officer and Director
$3.93M
@ $269.51 · 2025-03-25
CAMPBELL ELIZABETH S
Officer
$1.11M
@ $268.28 · 2025-03-24
MAUCH ROBERT P.
Chief Executive Officer
$1.30M
@ $260.93 · 2025-03-18
KRIKORIAN LAZARUS
Officer
$520,120
@ $260.06 · 2025-03-10
MAUCH ROBERT P.
Chief Executive Officer
$1.27M
@ $255.00 · 2025-03-03
COLLIS STEVEN HOWARD
Officer and Director
$3.66M
@ $251.08 · 2025-02-27
BATTAGLIA SILVANA
Officer
$1.21M
@ $242.24 · 2025-02-21
BATTAGLIA SILVANA
Officer
$383,792
@ $228.72 · 2024-12-20
KRIKORIAN LAZARUS
Officer
$454,754
@ $250.42 · 2024-12-03
COLLIS STEVEN HOWARD
Officer and Director
$12.20M
@ $243.97 · 2024-11-25
COLLIS STEVEN HOWARD
Officer and Director
$5.21M
@ $242.16 · 2024-11-19
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😏Greed(72/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
COR
FearGreed
😐Neutral(58/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (72)
COR
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (58)
View ABBV Full AnalysisView COR Full Analysis

Frequently Asked Questions: ABBV vs COR

Is AbbVie Inc. or Cencora, Inc. more undervalued in 2026?▼

Based on our discounted cash flow model, COR trades at a -67.3% margin of safety (intrinsic value $198 vs. price $331), compared to ABBV's -71.5% margin of safety (intrinsic $172 vs. $295).

Which stock has a wider economic moat, AbbVie Inc. or Cencora, Inc.?▼

COR scores 95/100 (Wide moat), while ABBV scores 82/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is AbbVie Inc. in financial distress?▼

ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. COR scores 4.9 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which stock has higher return on invested capital, AbbVie Inc. or Cencora, Inc.?▼

ABBV earns 29.1% ROIC versus COR's 21.0%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, AbbVie Inc.'s or Cencora, Inc.'s?▼

COR's dividend earns a safety score of 94/100 (Very Safe), compared to ABBV's 39/100 (Unsafe). COR has raised its dividend for 3 consecutive years.